We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+22.9%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.54B
AUM Growth
+$381M
Cap. Flow
+$151M
Cap. Flow %
9.83%
Top 10 Hldgs %
42.85%
Holding
66
New
16
Increased
21
Reduced
18
Closed
6

Top Buys

Rank Stock Value
1
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$31.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.7M
3
RGNX icon
Regenxbio
RGNX
+$24.5M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$23.6M
5
ICUI icon
ICU Medical
ICUI
+$23.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$51.5M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$47.7M
3
ARRY
Array Biopharma Inc
ARRY
+$41M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$39.4M
5
CNC icon
Centene
CNC
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.68%
2 Financials 0.93%
3 Miscellaneous 0.83%
4 Communication Services 0.56%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$114M 7.41%
12,765,862
-3,852,914
-23% -$41M
PEN icon
2
Penumbra
PEN
$12.7B
$86.3M 5.6%
1,034,408
-5,800
-0.6% -$439K
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$81.1M 5.26%
11,375,852
-955,278
-8% -$6.04M
PBYI icon
4
Puma Biotechnology
PBYI
$468M
$64.2M 4.17%
1,725,414
+435,274
+34% +$15.9M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$61.9M 4.02%
972,696
-647,659
-40% -$39.4M
ATRA icon
6
Atara Biotherapeutics
ATRA
$92.3M
$56.2M 3.65%
109,365
+2,527
+2% +$1.05M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.99B
$52.7M 3.42%
902,578
+164,127
+22% +$7.87M
MOH icon
8
Molina Healthcare
MOH
$10.4B
$52.4M 3.4%
1,149,727
+344,181
+43% +$18M
PRTA icon
9
Prothena Corp
PRTA
$479M
$47.4M 3.08%
849,483
+195,758
+30% +$10.3M
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$43.8M 2.84%
696,386
-824,518
-54% -$51.5M
INCY icon
11
Incyte
INCY
$25.2B
$41.1M 2.67%
307,723
-144,264
-32% -$18.4M
GWPH
12
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$40.2M 2.61%
332,544
-33,524
-9% -$4.11M
ALDR
13
DELISTED
Alder Biopharmaceuticals
ALDR
$39.7M 2.58%
1,909,886
+989,336
+107% +$21.9M
XNCR icon
14
Xencor
XNCR
$1.94B
$38.1M 2.47%
1,592,526
+596,426
+60% +$14.4M
WVE icon
15
Wave Life Sciences
WVE
$993M
$35M 2.27%
1,271,097
+319,385
+34% +$8.92M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$34.4M 2.23%
934,343
+617,943
+195% +$15.6M
OXFD
17
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$31.1M 2.02%
2,004,849
+303,800
+18% +$4.34M
BSX icon
18
Boston Scientific
BSX
$67.9B
$29.8M 1.94%
1,200,099
+740,594
+161% +$18M
SYNH
19
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$29.1M 1.89%
+633,779
New +$31.5M
ELV icon
20
Elevance Health
ELV
$85.5B
$29M 1.88%
175,328
+98,105
+127% +$15.6M
CMRX
21
DELISTED
Chimerix, Inc.
CMRX
$27.6M 1.79%
4,325,055
+979,096
+29% +$5.55M
NBIX icon
22
Neurocrine Biosciences
NBIX
$15.7B
$26.9M 1.75%
+622,345
New +$26.7M
NDRM
23
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$24.5M 1.59%
924,304
-636,515
-41% -$15.8M
ICUI icon
24
ICU Medical
ICUI
$4.38B
$24.5M 1.59%
+160,543
New +$23.5M
RGNX icon
25
Regenxbio
RGNX
$638M
$24.5M 1.59%
+1,269,131
New +$24.5M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2017 Portfolio in Review

As of Q1 2017, Redmile Group held 66 positions worth $1.54B, up 33% from $1.16B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $151M of net new capital in Q1 2017, opening 16 new positions and adding to 21 existing holdings. Its largest new stake was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $51.5M trimmed.

  • Redmile Group's largest Q1 2017 buy was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.
  • Redmile Group added most to Alder Biopharmaceuticals in Q1 2017, an estimated $21.9M increase.
  • Redmile Group's biggest Q1 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $51.5M.
  • Redmile Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $47.7M.
  • Redmile Group's ten largest holdings make up 43% of its $1.54B portfolio in Q1 2017.
  • Redmile Group opened 16 new positions and closed 6 in Q1 2017.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $1.54B.

Based on Redmile Group's 13F filing for Q1 2017, filed 15 May 2017.